Content area

|
|

Dyskinesier ved Parkinsons sygdom: opdatering om nye billeddannende metoder og behandlingsmuligheder

Forfattere
Birgitte Liang Chen Thomsen1,2, Damian Marc Herz3,4, Hartwig Roman Siebner1,2,5 & Annemette Løkkegaard1,2 1) Neurologisk Afdeling, Bispebjerg og Frederiksberg Hospital 2) Det Sundhedsfaglige Fakultet, Københavns Universitet 3) Medical Research Council Brain Network Dynamics Unit at the University of Oxford, University of Oxford, UK. 4) Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, UK 5) MR Forskningssektion, Funktions- og Billeddiagnostisk Enhed, Hvidovre Hospital Ugeskr Læger 2017;179:V06160433
Reference: 
Ugeskr Læger 2017;179:V06160433
Blad nummer: 
Sidetal: 
2-6
Dyskinesia in Parkinson’s disease: an update on new neuroimaging methods and treatment possibilities
Levodopa-induced dyskinesia (LID) represents a severe adverse effect of long-term treatment of Parkinson’s disease with levodopa. Neuroimaging studies have contributed to our understanding of LID and may help to identify patients at risk of developing LID. Amantadine can be used for the treatment of LID, and novel drugs are under development. Deep brain stimulation of the subthalamic nucleus and globus pallidus internus alleviates LID, the former indirectly by reducing levodopa intake, the latter through direct effects. Repetitive transcranial magnetic stimulation has been shown to transiently improve LID.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anders Beich | 24/04
1 Kommentar
af Brian Jørn Lerche | 24/04
4 kommentarer
af Søren Gunnar Friborg | 23/04
1 Kommentar
af Lars Borly | 22/04
1 Kommentar
af Hanne Hulgaard | 22/04
1 Kommentar
af Per Kristian Kruhøffer | 21/04
1 Kommentar
af Kristian Rørbæk Madsen | 21/04
6 kommentarer
af Alice Kunkel | 21/04
1 Kommentar
af Klaus Larsen | 18/04
2 kommentarer
af Elo Aagaard Rasmussen | 17/04
5 kommentarer